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Abstract 
Background: Large observational implementation studies are needed to triangulate the findings from 
randomized control trials (RCTs) as they reflect “real world” everyday practice. In a pilot study, we 
attempted to provide additional and complementary insights on the real life treatment of allergic 
rhinitis using mobile technology.   
Methods: A mobile phone app (Allergy Diary, freely available Google Play and Apple App stores) 
collects the data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, 
ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list 
including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 
countries.   
Results: A total of 2,871 users filled in 17,091 days of VAS in 2015 and 2016. Medications were 
reported for 9,634 days. The assessment of days appeared to be more informative than the course of 
the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they 
appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed 
differentiation between treatments within or between classes (intranasal corticosteroid use containing 
medications and oral H1-antihistamines). The control of days differed between no [best control], 
single or multiple treatments (worst control). 
Conclusions: The present study confirms the usefulness of the Allergy Diary in accessing and 
assessing everyday use and practice in allergic rhinitis. This pilot observational study uses a very 
simple assessment (VAS) on a mobile phone, shows novel findings and generates new hypotheses.    
 
Key words: mHealth, mobile technology, observational study, rhinitis, treatment  
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AHA: Active and Healthy Aging 
AR: allergic rhinitis 
ARIA: Allergic Rhinitis and its Impact on Asthma 
AZE: Azelastine 
EIP: European Innovation Partnership 
EU: European Union 
FF: Fluticasone furoate 
FP: Fluticasone propionate 
GRADE: Grading of Recommendations, Assessment, Development and Evaluations 
ICT: information and communications technology 
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INCS: Intranasal corticosteroid 
MACVIA: Contre les MAladies Chroniques pour un VIellissement Actif  
MASK: MACVIA-ARIA Sentinel NetworK 
MF: Mometasone furoate 
MP-AzeFlu: Azelastine-Fluticasone propionate 
OAH: Oral H1-antihistamines 
OTC: over the counter 
RCT: randomized controlled trial 
RTSS: rhinoconjunctivitis total symptom score  
REST: Restricted analysis 
TNSS: Total nasal symptom score 
VAS: visual analogue scale 
 
Introduction 
The treatment of allergic rhinitis (AR) is complex as many drugs are available in oral and/or topical 
formulations. Many guidelines for AR are evidence-based  and have led to a better understanding and 
management of AR.  However, guidelines are mostly based on randomized controlled trials (RCTs), 
typically undertaken on highly selected populations, often with limited/unclear generalizability to 
routine care contexts (1-3).   
Large observational implementation studies are needed to triangulate RCT as they reflect “real world” 
every day use and practice more closely than RCTs in terms of the heterogeneous patient populations 
included, and the variety of medical interventions assessed (4). In RCTs, each subject is randomly 
assigned to a treatment or control group, whereas observational studies examine the possible effect of 
a treatment on subjects where the investigator has no control over the experiment and cannot 
randomize subject allocation (5). However, observational studies provide clinically relevant 
information in addition to RCTs.  
MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis), an information and 
communications technology (ICT) system centered around the patient (6-8), is one of the 
implementation tools of the European Innovation Partnership on Active and Healthy Ageing (EIP on 
AHA) (9, 10). A mobile phone app (Allergy Diary), launched in 22 countries (11), uses visual 
analogue scales (VAS) to assess  rhinitis control and work impairment (12), as well as a treatment 
scroll list including all medications customized for each country. The use of mobile health 
applications to conduct observational clinical studies requires the establishment of feasibility. 
This pilot study was undertaken to provide additional and complementary insights to evidence derived 
from RCTs in the real life treatment of AR. The Allergy Diary(11) was used to assess the control of 
rhinitis by medications.  
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Methods 
Design of the study 
This prospective observational study of a mobile application – the Allergy Diary – was used to assess 
self-reported medication use.  
The objectives of this study were (i) to report the median VAS global-measured values depending on 
the treatment received, (ii) to undertake a sensitivity analysis by comparing the results for one day of 
treatment, the full data set and a restricted data set (i.e. 2016 and the first two weeks of treatment), 
(iii) to investigate users receiving single prescribed treatments (MP-AzeFlu, FF or MP monotherapy 
for rhinitis) and those receiving several treatments for rhinitis on the same day (co-medication for 
rhinitis) and (iv) to assess initial severity assessed on the first day of use of the App on the treatment 
reported by users.  
 
Users  
All consecutive users from May 21, 2015 to November 8, 2016 were included with no exclusion 
criteria. Some demographic characteristics (age, sex, country and language) were recorded. The 
Allergy Diary was used by people who found it on the internet, Apple App store, Google Play or any 
other way. The pages of the App are on the Euforea-ARIA website (www.euforea.eu/about-
us/aria.html).. A few users were clinic patients who were asked by their physicians to use the app. 
Users were not requested to complete the diary for a minimum of days. However, due to 
anonymization of data, no specific information on the route of access to the app could be gathered as 
previously reported (11, 13). 
 
Setting 
Users from 15 countries filled in the Allergy Diary (Table 1). 
 
Allergy Diary 
Geolocalized users assess their daily symptom control using the touchscreen functionality on their 
smart phone to click on five consecutive VAS (i.e. general, nasal and ocular symptoms, asthma and 
work) (Figure 1 online). Users input their daily medications using a scroll list which contains all 
country-specific OTC and prescribed medications available (Figure 2 online). The list has been 
populated using IMS data. 
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Ethics 
The Allergy Diary is CE1 registered but it was not considered by the Ethical Committee of the 
Cologne Hospital of the MHRA (Medicines and Healthcare products Regulatory Agency - GOV.UK) 
as a medical device given that it does not provide any recommendations concerning treatment or 
diagnosis. The terms of use were translated into all languages and customized according to the 
legislation of each country, allowing the use of the results for research purposes. The example of the 
UK terms of use have been provided in a previous paper (11).  
The data were anonymized except for the geolocalized data which are never totally anonymous. This 
issue was carefully considered in the first paper on the Allergy Diary. (11)  
An Independent Review Board approval was not required.  
 
Outcomes 
In this study, initial characteristics (Table 1 online) (11),  four VAS measurements (VAS-global 
measured, VAS-nasal, VAS-ocular, and VAS-work, Table 2 online) and a calculated VAS-global 
calculated score (VAS-nasal + VAS-ocular divided by 2) were considered. The VAS-asthma was not 
analyzed as there was a change in the question on June 1, 2016. VAS levels range from zero (not at all 
bothersome) to 100 (very bothersome). Independency of VAS questions was previously assessed 
using the Bland and Altman regression analysis (13, 14). 
Days reported by users included days with or without treatment. 
The present study is another Allergy Diary study. None of the data used in the first paper (11) were 
used in this study. Data of the second paper were used but the analysis was totally different since we 
analyzed medication effects whereas in the former paper the focus was on work productivity (13). 
Selection of medications 
The International Nonproprietary Names classification was used for drug nomenclature (15). 
Monotherapy was defined as days when only one single medication for rhinitis was taken. Poly-
medication (co-medication) was defined as days with two or more medications for rhinitis. Asthma 
medications were not considered in poly-medication.   
Avamys® (FF) and Dymista® (MP-AzeFlu) were the only prescribed medications. MF is OTC in the 
UK (since mid 2015), Sweden (since Feb 2013), Finland (since Nov 2012) and we excluded users 
with possible OTC drugs. 
Biases 
There are potential measurement biases when using apps since the information collected is usually 
restricted. The self-reported nature of the data represents another bias inherent to App usage. A bias 
might be introduced because app users may be a selected subset, and are therefore not fully 
representative of all patients with rhinitis. Finally, it is not known whether users fill in their 
information before of after treatment for a given day. 
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Size of the study 
In this exploratory pilot study, all registered users between May 21, 2015 and November 8, 2016 were 
included to obtain the best possible estimates for the specified time window.    
 
Statistical methods  
A non-Gaussian distribution was found for the data. Non-parametric tests and medians (and 
percentiles) were used. 
Some users reported VAS scores more than once a day. Before analysis, we proposed that if the same 
treatment was reported and the daily variation was under 30%, the highest VAS score would be used 
as previously (13). In the full data set, there were 631 days with multiple values, and of these only 133 
(1.4%) had a variation > 30%. We decided that this number was not sufficient enough to impact the 
results and we used the highest value for the day. 
 
Analysis of the data 
The study was not a longitudinal study because (i) there was an insufficient number of users reporting 
data over a period of 5 days (335), (ii) there was no clear pattern of treatment in users, (iii) most users 
did not report a stable and continuous period of treatment and (iv) many users modified their 
treatment during the reporting period. Moreover, in the study, users are unselected and it is not known 
whether the first day of use was the first day of treatment. Although there may be causal inferences, 
we used cross-sectional data for days of treatment. We analyzed the full data set and performed the 
following sensitivity analyses: (i) a restricted analysis (REST) was performed on up to the first 15 
days of treatment in users who initiated their study in 2016, and (ii) the first day of reporting was 
analyzed since there was a higher level of VAS on day 1 than on the other days and there were more 
users with a single day than with multiple days. 
Medications used and compliance to treatment: All users were investigated for 2015 and 2016 and 
the number of days of reporting VAS levels were assessed. We then studied 2016 and examined the 
compliance to treatment in users who reported 5-7 days, 8-15 days and >16 days. In the latter group, 
only the first 30 days were investigated. Compliant users were those reporting ≥ 80% consecutive 
days and ≥80% days with the same treatment. Uncompliant users were those reporting <80% days 
with the same treatment. Discontinuous users were those reporting < 80% consecutive days and ≥80% 
days with same treatment. We then checked the number of medications reported during the period of 
examination. 
Control of the disease: Using the full data set and REST, we studied median VAS levels for 
medications reported for at least 1,000 days and for days without medications. We used the global 
measured VAS as a primary end point and the other VAS measures (nose, eyes, work) as secondary 
end points (12). As this was a pilot study, only the primary end point was analyzed using the Kruskal-
Wallis test with Dunn’s post hoc analysis. 
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Prescribed medications: We then focussed on the three medications always prescribed i.e. those not 
available over the counter (MP-AzeFlu, FF and MF). For MF, we carefully checked the dates of OTC 
introduction for the different molecules in the different countries. We first analysed the frequency of 
days with monotherapy (FF and MF) or MP-AzeFlu and days with added medications (co-
medication). We then compared VAS global-measured levels the first day of use, REST and full data. 
Data were analyzed using the Kruskal-Wallis test with Dunn’s post hoc analysis. 
 
Results  
Users 
A total of 2,871 users filled in 17,091 days of VAS (Figure 1). There were 39% females, 44% males 
and 17% of unknow. The mean age was 37 ± 17 years. The age of the users (by days) is reported in 
Figure 3 online and shows that the App was used from 12 to 80 years of age with a peak at 30-49 
years. 
 Medications were reported for 9,634 days and no medications for 7,457 days. 2,741 users (1,686 with 
medication) responded “Yes” to Q1 (i.e. “Do you have rhinitis?) and 130 users (52 with medication) 
responded “No” but ticked any nasal symptom (Q3). VAS-work was only included in the App after 
June 1, 2016 and fewer days with VAS are available (Table 1).  
Among the 17,091 VAS days, all users filled in VAS-nasal and VAS-ocular but 436 days were not 
filled in for VAS-global measured (”No” to Q1).  
 
Treatments and compliance 
The number of reported days per user ranged from one (1,539 users) to over 60 (2-7 days: 911 users, 
8-15 days: 149 users, >15 days: 266 users). Among the 2016 users, 98 reported 5 to 7 days, 85 8-14 
days and 181 over 15 days (Table 2). Only 33.9% of users reported a single mediation and 42.1% 
reporting over eight days of VAS used three treatments. In users reporting five or more days of VAS, 
compliance to treatment ranged from 32.9% to 40.8% (Table 2). 
The treatments reported included 504 drugs and 86 INNs or combinations associated to medications. 
475 users received an asthma treatment.  
 
Overall results  
Data obtained were extremely consistent for different VAS measurements (global measured, nose, 
eyes and work) or different analyses (full data set and restricted data set across all outcomes) (Table 
3). In the full data set, VAS scores were greater on days with treatment (median, 25-75 percentiles for 
VAS global measured: 25 (9-50)) than on days without treatment (11 (2-33)) (p<0.0001). Similar 
levels of VAS were reported on days without treatment in users who never reported any medication 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.[ 
(15 (0-47)) and in those who were sometimes treated (Uncompliant: 15 (5-37)). There were minimal 
differences in recorded VAS scores between MP-AzeFlu (19 (8-45)), FF (22 (4-52)) and MF (25 (11-
48)).   
The median scores for the six medications imputed for over 1,000 days showed that days with any of 
the three medications containing INCS had a lower VAS global measured level than days in which 
OAH were reported.   
Single therapy and co-medication 
The results were extremely consistent since, for all medications apart from desloratadine, days under 
monotherapy (or MP-AzeFlu) had significantly lower VAS-global measured median levels than days 
with co-medication (Table 4).  
Prescribed medications 
Only three medications containing INCS were exclusively prescribed. MF was OTC in some 
countries but the users were low in number and therefore not included in the analysis. There were 
major differences between treatments in the percentage of mono- and co-medication including OAH 
used. MP-AzeFlu was used more often alone (64-68%) than FF (32-37%) or MF (38-46%) and these 
trends were found in day 1 and persisted across the study (Figure 2). 
The results for the three INCS-containing medications as rhinitis-monotherapy, treatment with an oral 
H1-antihistamine (OAH) or any other medication for rhinitis (poly-medication) are presented in Table 
5. For the full data set, MP-AzeFlu had a median VAS score (14(6-33,5)) similar to FF monotherapy 
(15(0-39)) and MF monotherapy (17(8-32)), but significantly lower than FF + OAH (31(14-58)) or 
MF + OAH 34(16-58). On the other hand, MP-AzeFlu + OAH had a VAS score (33(13,5-54)) similar 
to FF or MF + OAH.  Similar trends were observed for REST and the results of Day 1. VAS levels 
were higher for Day 1 than for REST and the full data set for all medications and combinations.    
 
Discussion 
The feasibility of using mobile health applications to conduct observational clinical studies requires 
assessment: (i) The present study confirms the usefulness of the Allergy Diary in accessing and 
assessing everyday use and practice in AR. (ii) This observational study, using a very simple 
assessment (VAS) on a cell phone, shows novel concepts concerning our knowledge of AR treatment 
and should be considered as an exploratory pilot study hypothesis generating. (iii) In real life, the 
assessment of days appears to be informative. (iv) The Allergy Diary allows the differentiation 
between treatments. (v) The control of days differs between no (best control), single or multiple 
treatments (worst control).  
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Strengths and limitations  
Smart devices and Internet-based applications are already used in rhinitis (16-21) but none have 
assessed real life treatment in a large number of users. The strengths of mobile technology include its 
wide acceptance and easy use, but there is a need to use appropriate questions, and results should be 
assessed by pilot studies. This pilot study was based on 2,871 users who filled, in 17,091 days of 
VAS. 
Data obtained were extremely consistent for different VAS measurements (global measured, nose, 
eyes and work) or different analyses (full data set, day 1 and REST). In a previous paper, we showed 
that there were strong to very strong correlations between the overall control of rhinitis and work 
VAS (13). 
In the present study, the definition of having rhinitis is purely users’ dependent.  Since the definition 
of rhinitis is not clear to the users, other conditions such chronic rhinosinusitis, or nasal septal 
deviation could have been considered as allergic rhinitis. Although the App does not allow to assess 
all the analyses proposed to differentiate between these diseases, sneezers and blockers will be 
differentiated in the next analysis as previously done (22). However, we did not do it in the present 
study (i) because an insufficient number of users and (ii) in this pilot analysis, we wanted to mimic a 
real life study. From our experience in GPs, differentiation between allergic and non-allergic rhinitis 
is difficult and most GPs do not attempt to make any differences between nasal symptoms (1, 23, 24).  
The study as already mentioned has no pretentions of reflecting the general population because (i) 
only a shot was taken into account, (ii) people using an App are not representative of the general 
population and (iii) the users reported few days few days. However, the sample size is important and 
according to the Law of Large Numbers, the characteristics of a random sample approach the 
statistical characteristics of the population from which the sample is extracted  when the sample size 
increases.  
Compliance is difficult to analyse without a real assessment by electronic pill counters or inhalers. 
These do not exist for nasal products or are just in testing. Questionnaires can be used but it appears 
that real life data are more appropriate. However, it should be emphasized that users may not report 
all medications used. 
Longitudinal data capture was very challenging because treatment trajectories are specific for almost 
each user and most users have gaps in treatment days when they are well-controlled, hence the focus 
on a cross-sectional analysis on days of treatment.   
 
Interpretation of the results and generalizability 
The real world assessment of the Allergy Diary using VAS allows assessment of treatment efficacy by 
days, which may represent a more objective estimation of AR treatments than patients’ comments 
since: (i) it is known that AR is a highly variable disease, and control varies widely between days in 
relation to allergen exposure, (ii) patients are not always compliant with their treatment, (iii) patients 
often stop treatment when they feel better (as found by the study but not shown) and (iv) patients 
increase their treatment when uncontrolled. 
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VAS scores were greater on treatment days than on days without treatment, suggesting that users 
reporting no treatment had milder disease than those who were occasionally treated. However, median 
VAS levels on days without treatment were similar in users who never reported any medication use 
and in those who were occasionally treated. Days without treatment were better controlled than days 
with treatment and days with a single treatment were better controlled than days with multiple 
treatments. These data suggest that, in real life, patients treat themselves when they suffer from 
symptoms and stop their treatment when they are controlled. This accords with previous data (25, 26). 
This study, using objective data, confirmed that adherence is poor. Most patients with rhinitis may 
have mild and/or intermittent disease that does not need a regular treatment to achieve control. The 
concept of pro-active medication (27) - the patient starting treatment when experiencing symptoms 
and continuing for a few days after getting control -  may be of great interest and could be tested with 
the App. In asthma, self-guided treatment was found to be of interest (27-29). Such real life findings 
may ultimately affect the way in which guidelines are constructed to align them more with human 
behaviour. 
This observational study made it possible to differentiate OAH and INCS, confirming known data, 
(30) but may be able to differentiate between OAH when more data are analyzed. It could also 
differentiate the three medications containing INCS: FF, MF and MP-AZeFlu and confirm previous 
studies, (31) extending our understanding of how AR treatment is used. RCTs showed that MP-
AzeFlu is more effective than single components available in pharmacies (32) or components using 
the same formulation (33). However, observational studies comparing prescribed medications 
containing INCS are not available. In the present study, a clear difference was found between 
medications.  Disease control assessed by VAS was similar in users who reported a single treatment 
for the three medications and was similarly increased in those with co-medication. However, a major 
difference is that around one third of MP-AzeFlu received the treatment without co-medication 
whereas FF or MF users required co-medication in 31 to 46%. Although this is a pilot study, over 
1,000 days of treatment were reported for each medication. A bias may however be confounding by 
indication. 
 
Conclusions 
 
This observational study shows highly consistent results between different outcomes (VAS levels), 
days of treatment or medications.  It appears possible to use this approach to better tailor treatments to 
individuals. 
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Table 1. Country and number of users recording Visual Analogue Scale score using the Allergy 
Diary in the full data set 
Country VAS measurements (days)  
VAS measurements ( 1           2 to 7 8 to 14 >14 Total 
Austria 81 (55.5%) 48 4 13 146 
Belgium 22 (51.2%) 18 1 2 43 
Denmark 12 (52.2%) 8 1 2 23 
Finland 10 (43.5%) 8 2 3 23 
France 232 (69.0%) 84 7 13 336 
Germany 74 (50.7%) 52 6 14 146 
Greece 8 (57.1%) 5 0 1 14 
Italy 379 (55.4%) 211 38 56 684 
Lithuania 18 (35.3%) 16 5 12 51 
Netherland 60 (54.5%) 35 7 8 110 
Poland 157 (60.1%) 82 10 12 261 
Portugal 305 (49.9%) 226 28 52 611 
Spain 64 (28.3%) 59 31 72 226 
Sweden 18 (52.9%) 12 2 2 34 
UK 86 (60.1%) 43 6 8 143 
Total   1526 (53.5%) 907 (31.8%) 148 (5.2%) 270 (9.5%) 2851 
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Data from Australia, Brazil, Canada, Mexico and Switzerland were excluded due to the low number of users 
(enrolment started in October 2016) 
 
 
Table 2: Compliance to treatment in users reporting ≥ 5 days of VAS in 2016 
Treatment 
reporting 
(days) 
N Pattern** Number of treatments during the reporting 
 Compliant  Discontinuous 
  
Un-compliant  1 2 3 ≥4 
5-7     98 40 (40.8%) 12 (10.2%) 46 (47%) 41 (41.8%) 33 (33.7%) 21  (21.4%)  3 (3.1%) 
8-14     85 28 (32.9%) 17 (20%) 40 (47.1%) 27 (31.7%) 20 (23.5%) 19 (22.3%) 19 (22.3%) 
15-30 * 181 71 (39.2%) 18 (10%) 92 (50.1%) 52 (28.7%) 55 (30.4%) 37 (19.9%) 37 (19.9%) 
*: Assessment of day 1- up to day 30 in users who reported ≥ 15 days of VAS 
**: Compliant: reporting ≥ 80% consecutive days and ≥80% days with treatment. Un-compliant: reporting 
<80% days with treatment, Discontinuous: reporting < 80% consecutive days and ≥80% days with treatment. 
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Table 3: Median Visual Analogue scale [VAS] scores recorded in Allergy Diary according to 
inputted rhinitis treatment 
 
 VAS   
Count 
Users Eyes VAS Nose VAS Asthma 
VAS 
global_ meas 
VAS 
global_ 
calc VAS 
fit_work VAS
No treatment 7457  
 
1712 5 [0-24] 
[7457] 
13 [1-39] 
[7457] 
0 [0-14] 
[5167] 
13 [1-38] 
[7250] 
11 [2-33] 
[7457] 
5 [0-19] 
[2365] 
No treatment 
rest 
4038 1602 9 [0-32,75]
[4038] 
22 [5-50]
[4038] 
1 [0-18]
[2462] 
22 [5-50]
[3878] 
19 [5-41] 
[4038] 
9 [0-28]
[1170] 
No medication 
[at any time for 
the user] 
3168 
 
1116 
 
6 [0-27] 
[3168] 
 
16 [1-47]
[3168] 
 
0 [0-13]
[2132] 
 
15 [0-47] a 
[3021] 
 
13,5 [1,5-37] 
[3168] 
 
5[0-19]
[1028] 
 
No medication 
[for some days 
only for the user] 
10109 
 
596 6 [0-26] 
[10109] 
 
16 [5-38]
[10109] 
 
1 [0-18]
[7139] 
 
15 [5-37]  b 
[9929] 
 
12,5 [4-32] 
[10109] 
 
8[0-24]
[3129] 
 
With treatment 9634 
 
1755 10 [0-35] 
[9634] 
25 [9-51] 
[9634] 
6 [0-29] 
[7001] 
25 [9-50] c 
[9408] 
19 [7-42] 
[9634] 
14 [3,25-37] 
[2834] 
With treatment 
rest 
5489 1600 14 [1-41] 
[5489] 
30 [11-56]
[5489] 
8 [0-36]
[3793] 
31 [13-55]
[5332] 
25 [10-47] 
[5489] 
18 [5-42]
[1514] 
FF 1252 226 10 [0-33] 
[1252] 
22 [4-51]
[1252] 
4 [0-32]
[954] 
22 [4-52] d 
[1223] 
18 [3-42] 
[1252] 
16 [4-38]
[386] 
FF rest 783 200 13 [0-37] 
[783] 
28 [11-53,5]
[783] 
9 [0-36]
[557] 
28 [11-53,5]
[771] 
22,5[ 8,5-45] 
[783] 
17[5,25-37]
[254] 
MP-AzeFlu 1628 195 9 [0-28] 
[1628] 
 
20 [7-46] 
[1628] 
 
4 [0-22] 
[1244] 
 
19 [8-45]  e 
[1601] 
 
15 [6-38] 
[1628] 
 
10 [2-27] 
[524] 
 
MP-AzeFlu rest 748 158 13 [2-33,25]
[748] 
27 [11-53]
[748] 
 
4,5 [0-24]
[526] 
27 [12-50]
[732] 
 
23 [9-42,625] 
[748] 
 
21,5 [8-
37,25] [236] 
Desloratadine 
 
1102 319 19 [1-48] 
[1102] 
35 [13-58]
[1102] 
12 [0-41]
[767] 
34 [15-55] f   
[1076] 
28 [12-51] 
[1102] 
28 [10-50]
[325] 
Desloratadine 
rest 
732 283 20 [1-47,25]
[732] 
35 [13-61]
[732] 
8 [0-34]
[482] 
36 [16-59]
[722] 
28 [11-51,5] 
[732] 
23 [9-47]
[205] 
Cetirizine 1293 
 
378 13 [1-47] 
[1293] 
23 [8-57]
[1293] 
8 [0-31]
[866] 
28 [9-58] g 
[1270] 
22 [7-49,5] 
[1293] 
13 [6-40]
[375] 
Cetirizine rest 945 356 14 [1-48] 
[945] 
28 [10-59] 
[945] 
7 [0-34] 
[604] 
32 [12-60] 
[924] 
25,5 [9-50,5] 
[945]  
21 [7-46] 
[229] 
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MF 1368 211 9 [0-32] 
[1368] 
24 [11-48]
[1368] 
3 [0-17]
[951] 
25 [11-48] h 
[1366] 
18 [9-38] 
[1368] 
13 [4,75-36]
[440] 
MF rest 693 193 12 [0-38] 
[693] 
28 [12-56] 
[693] 
3 [0-29,5] 
[447] 
29 [12,5-55] 
[691] 
22,5 [9,5-45] 
[693] 
9 [0-29] [185] 
Rest: restricted to 15 days survey in 2016 study, meas: measured, calc: calculated 
Results in medians and [25-75 percentiles] 
MP-AzeFlu: Intranasal azelastine and fluticasone propionate, FF: fluticasone furoate; MF: mometasone furoate;  
Square brackets: number of days 
 
Statistical analysis 
a, b, c: Kruskall Wallis p<0.0001, Bonferroni-Dunn’s post hoc analysis: a/b: NS, a/c: p<0.05, b/c: p<0.05 
d,e,f,g,h: Kruskall Wallis p<0.0001, Bonferroni-Dunn’s post hoc analysis 
 
 AzeFlu FF Desloratadine Cetirizine MF 
AzeFlu (e)  NS P<0.05 P<0.05 P<0.05 
FF (d) NS  P<0.05 P<0.05 P<0.05
Desloratadine (f) P<0.05 P<0.05  P<0.05 P<0.05 
Cetirizine (g) P<0.05 P<0.05 P<0.05   
MF ( h) P<0.05 P<0.05 P<0.05 NS  
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Table 4: Daily global measured VAS (full data set) 
 MP AzeFlu FF MF Loratadine Cetirizine 
 Single CoM Single CoM Single CoM Single CoM Single CoM 
N 1039 589 406 846 625 743 610 492 622 671 
Minimum 0 0 0 0 0 0 0 0 0 0 
Maximum 100 99 100 100 100 100 100 100 100 100 
Median 14.0 32.0 15.0 25.5 17.0 34.0 34.0 35.0 22.0 33.0 
25% 6.0 13.0 0.0 6.0 8.0 17.0 14.0 15.0 8.0 10.0 
75% 33.5 54.0 39.0 55.0 32.0 55.0 53.0 59.0 53.0 61.5 
 p<0.001 p<0.001 p<0.001 NS p<0.001 
Single: single treatment, Poly:, p value by Mann-Whitney U test 
 
Table 5: Median global visual analogue scale scores measured in days with INCS-containing  
medications  
             Full data set     Restricted data set [REST]            Day 1 
  Median [25-75] 
[day counts] 
Users Median [25-75]  
[day counts] 
Users Median [25-75] 
[day counts] 
FF  15[0-39] [377] 107 21[4-44,25] [222] 92 40[24-54] [57] 
+ OAH 25[5-55] [803] 149 31[14-58] [514] 134 59[33-76] [93] 
+ other co-
medication   
26[12-34] [43] 19 25[10,5-34] [35] 14 23[13,5-23] [3] 
 
AMP-  14[6-33,5] [1023] 149 21,5[9-44] [458] 123 36[16,25-58,25] [90] 
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Aze Flu   + OAH 33[13,5-54] [459] 71 41[20,75-59,25] [228] 56 56[27,5-70] [32] 
+ other co-
medication   
25[13-54] [119] 31 24[10,75-42] [46] 14 44[30,25-83,25] [12] 
 
MF   17[8-32] [623] 99 19[6-38] [270] 89 32[18-57] [53] 
+ OAH 34[16-58] [606] 137 40[17-62] [386] 124 54,5[30-78] [76] 
+ other co-
medication   
31[21-48] [137] 20 30[19,5-50] [35] 14 53[50-58] [9] 
FF: fluticasone furoate; OAH: oral anti-histamine; MF: mometasone furoate, MP-AzeFlu: Intranasal azelastine 
and fluticasone propionate, 
Statistical analysis   
 AzeFlu AzeFlu  + OHA FF FF + OHA MF MF + OHA 
AzeFlu  P<0.05 NS P<0.05 NS P<0.05 
AzeFlu + OHA P<0.05  P<0.05 P<0.05 P<0.05 NS 
FF NS P<0.05  P<0.05 NS P<0.05 
FF + OHA P<0.05 NS P<0.05  P<0.05 P<0.05 
MF NS P<0.05 NS P<0.05  P<0.05 
MF + OHA P<0.05 NS P<0.05 P<0.05 P<0.05  
Statistical analysis by Kruskall-Wallis test (p<0.0001) and Dunn’ post hoc analysis 
P<0.05: significant  for full data set and REST, p<0.05: significant for full data set only 
Users with co-medication other than OAH were not included due to their low number 
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Figure 1: Flow chart  
 
 
Figure 2: Percentage of days with single 
 
 
 
 
treatment 
 
